Drugs / Efimosfermin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06920043 | Apr 2025 → Jul 2028 expected | NAFLD1, metabolic dysfunction-associated steatohepatitis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT04880031 | Sep 2021 → Oct 2025 | metabolic dysfunction-associated steatohepatitis | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | GlaxoSmithKline | Regulatory GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation by the European Medicines Agency (EMA) for the treatment of MASH. |
| 2025-11-07 | GlaxoSmithKline | Results GSK presents data from its advancing liver pipeline at AASLD 2025 gsk.com ↗
Late breaking results for once-monthly efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), supporting the start of phase III clinical trials |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efimosfermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06920043 ↗ |
| Known as | Efimosfermin alfa | “Efimosfermin alfa (efimosfermin, formerly BOS-580) is a long-acting, engineered variant of FGF21 designed to have a prolonged half-life.” PMID 40484014 ↗ Jun 2025 |
| Modality | Protein / enzyme biologic | “Efimosfermin alfa (efimosfermin, formerly BOS-580) is a long-acting, engineered variant of FGF21 designed to have a prolonged half-life.” PMID 40484014 ↗ Jun 2025 |
| Route | Subcutaneous | “Efimosfermin will be administered by subcutaneous injection” NCT04880031 ↗ |